Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPemBra: Pembrolizumab +/- Dabrafenib and Trametinib in BRAFV600-Mutated Metastatic Melanoma
NCT02625337Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by Netherlands Cancer Institute. Status: unknown.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02625337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625337.